英諾特(688253.SH):暫未部署DeepSeek
格隆匯3月17日丨英諾特(688253.SH)在互動平臺表示,在診斷方面,公司呼吸道熒光九項產品(國械注準20163401648)可利用數碼生物顯微鏡(備案號:蘇蘇械備 20222057)輔助結果判讀,該儀器的系統原理是將AI算法與熒光檢測技術深度融合,實現了智能化的數據分析與處理,有效減輕醫務人員負擔,大幅度提升熒光判讀準確性。目前呼吸道熒光九項產品營收佔比較小,敬請注意投資風險。公司目前暫未部署DeepSeek。公司將持續關注DeepSeek等新技術的發展動態,審慎評估和探索相關技術在公司研發、生產和營銷等方面的應用可能性,持續提升數字化智能化水平,推動公司可持續高質量發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.